Table 1. Baseline Characteristics of Study Population by Quartiles of FT3 Level.
| Quartiles of FT3 level (pg/mL) |
|||||
|---|---|---|---|---|---|
| <2.53n = 20 | 2.53–2.76n = 16 | 2.77–3.19n = 18 | >3.19n = 17 | P value | |
| Age (year) | 57 (46–63) | 48 (36–60) | 56 (49–66) | 54 (49–59) | 0.112 |
| Female (n, %) | 10 (50.0%) | 6 (37.5%) | 5 (27.8%) | 3 (17.6%) | 0.017 |
| Smoking, (n, %) | 4 (20.0%) | 6 (37.5%) | 7 (38.9%) | 9 (52.9%) | 0.024 |
| BMI (kg/m2) | 24.2 (3.79) | 24.91 (5.89) | 24.63 (1.7) | 25.87 (2.92) | 0.635 |
| Blood pressure | |||||
| Systolic (mmHg) | 112 (18) | 107 (18) | 119 (19) | 117 (14) | 0.231 |
| Diastolic (mmHg) | 70 (9) | 71 (11) | 71 (11) | 76 (11) | 0.268 |
| NYHA III–IV class, (n, %) | 18 (90.0%) | 11 (68.7% | 13 (72.2%) | 13 (76.5%) | 0.411 |
| Comorbidities (n, %) | |||||
| Atrial fibrillation | 4 (20.0%) | 4 (25.0%) | 2 (11.1%) | 2 (11.8%) | 0.026 |
| Diabetes mellitus | 5 (25.0%) | 2 (12.5%) | 3 (16.7%) | 1 (5.9%) | 0.439 |
| Dyslipidemia | 7 (35.0%) | 6 (37.5%) | 5 (27.8%) | 6 (35.3%) | 0.924 |
| Anemia | 3 (15.0%) | 4 (25.0%) | 2 (11.1%) | 1 (5.9%) | 0.473 |
| Renal dysfunction | 4 (20.0%) | 5 (31.3%) | 4 (22.2%) | 2 (11.8%) | 0.592 |
| Medications, (n, %) | |||||
| ACEi/ARB | 11 (55.0%) | 10 (62.5%) | 15 (83.3%) | 12 (70.6%) | 0.291 |
| Beta blocker | 18 (90.0%) | 13 (81.3%) | 18 (100.0%) | 12 (70.6%) | 0.078 |
| Aldosterone antagonists | 13 (65.0%) | 8 (50.0%) | 11 (61.1%) | 6 (35.3%) | 0.498 |
| Diuretics | 19 (95.0%) | 15 (93.8%) | 17 (94.4%) | 14 (82.4%) | 0.482 |
| Cardiac MRI measurements | |||||
| LVEF (%) | 23 (6) | 24 (8) | 28 (9) | 28 (7) | 0.009 |
| LVEDV index (mL/m2) | 170.5 (72.1) | 162.2 (70.5) | 145.3 (61.7) | 132.5 (50.6) | 0.032 |
| LVESV index (mL/m2) | 137.1 (56.2) | 120.6 (60.4) | 129.3 (49.1) | 105.7 (53.5) | 0.073 |
| LV mass (g) | 142 (7) | 146 (9) | 149 (7) | 147 (8) | 0.154 |
| Presence of LGE | 13 (65.0%) | 10 (62.5%) | 7 (38.8%) | 3 (17.6%) | 0.015 |
| Presence of perfusion abnormality | 14 (70.0%) | 9 (56.2%) | 13 (72.2%) | 6 (35.3%) | 0.098 |
| Presence of metabolism abnormality | 10 (50.0%) | 7 (43.8%) | 3 (16.7%) | 3 (17.6%) | 0.058 |
| TSH (mIU/L) | 1.55 (0.89–3.5) | 2.32 (1.44–2.93) | 2.19 (1.52–3.1) | 0.86 (0.6–1.43) | 0.444 |
| FT4 (ng/dlL) | 1.25 (1.05–1.39) | 1.22 (1.13–1.27) | 1.21 (1.10–1.43) | 1.27 (1.09–1.43) | 0.291 |
| FT3 (pg/mL) | 2.29 (1.92–2.46) | 2.65 (2.60–2.70) | 3.01 (2.88–3.13) | 3.38 (3.24–3.61) | <0.001 |
Abbreviation: BMI, body mass index; NYHA, New York Heart Association; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LV, left ventricle; EF, ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; LGE, late gadolinium enhancement; TSH, thyroid stimulating hormone; FT4, free thyroxin; FT3, free triiodothyronine. The data are presented as n (%), median (first quartile, third quartile) or mean (SD).